Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acurx Pharmaceuticals Inc
(NQ:
ACXP
)
2.050
-0.020 (-0.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acurx Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
91 Biggest Movers From Friday
June 13, 2022
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Via
Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 10, 2022
Gainers bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day...
Via
Benzinga
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
June 09, 2022
Via
AB Newswire
Exposures
Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
June 06, 2022
Via
AB Newswire
Exposures
Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
March 28, 2022
Via
AB Newswire
Exposures
Product Safety
90 Biggest Movers From Yesterday
May 13, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered...
Via
Benzinga
Earnings Scheduled For March 17, 2022
March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is...
Via
Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
March 07, 2022
Via
AB Newswire
Acurx Pharmaceuticals’ Phase 2b Antibiotic Candidate To Treat C. Difficile Shows 100% Cure And 100% Sustained Cure In Potentially Transformative Study (NASDAQ: ACXP)
February 17, 2022
Via
AB Newswire
53 Biggest Movers From Friday
January 24, 2022
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 21, 2022
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-...
Via
Benzinga
Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)
January 03, 2022
Via
AB Newswire
If A Santa Claus Rally Comes To Town, Expect Acurx Pharmaceuticals To Be On The Lead Sleigh…Here’s Why (NASDAQ: ACXP)
December 22, 2021
Via
AB Newswire
With A Phase 2b Trial In Progress, Acurx Pharmaceuticals May be The Most Undervalued Biotech On The Market…Here’s Why (NASDAQ: ACXP)
December 16, 2021
Via
AB Newswire
Acurx Pharmaceuticals Stock Spikes 10% After Reaching Phase 2b Milestone Evaluating Ibezapolstat To Treat CDI (NASDAQ: ACXP)
December 09, 2021
Via
AB Newswire
Acurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP)
November 30, 2021
Via
AB Newswire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:
Via
Benzinga
Acurx Pharmaceuticals’ Drug Candidate Ibezapolstat Continues To Score Clinical Wins In Treating C. Difficile (NASDAQ: ACXP)
November 10, 2021
Via
AB Newswire
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...
Via
Benzinga
Exposures
COVID-19
Product Safety
AcurX Pharmaceuticals’ C. Difficile Drug Candidate Could Fetch $800 Million On A Peer Comparison Basis (NASDAQ: ACXP)
October 20, 2021
Via
AB Newswire
Exposures
Product Safety
VIDEO Report: Acurx Pharmaceuticals’ Ibezapolstat In Focus As A Best-In-Class Treatment For Gram Positive Infections (NASDAQ: ACXP)
September 21, 2021
Via
AB Newswire
CEO In Focus: Acurx Pharma CEO Confident His Company’s Phase 2b Ibezapolstat Trial Can Lead To A Front-Line Treatment For C. difficile (NASDAQ: ACXP)
September 15, 2021
Via
AB Newswire
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts
September 13, 2021
New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing...
Via
Newsfile
Topics
Death
Derivatives
Initial Public Offering
Exposures
Death
Derivatives
Intellectual Property
Acurx Pharmaceutical’s Reaches Another Milestone With Russell Microcap Inclusion; Shares Extend August Gains (NASDAQ: ACXP)
September 03, 2021
Via
AB Newswire
Acurx Pharmaceutical’s Is Disruptive To The Antibiotics Landscape- That’s Great News For Patients With Gram-Positive Infections (NASDAQ: ACXP)
September 01, 2021
Via
AB Newswire
Acurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better Drugs That Target Gram-Positive Infections
August 25, 2021
Via
AB Newswire
Acurx Pharmaceutical’s On Pace To Change The Antibiotics Landscape; Trial Data Shows 100% Sustained Clinical Cure In Treating Gram-Positive Infection CDI
August 17, 2021
Via
AB Newswire
Drug Makers Overseas Are Gaining A Competitive Advantage In The Antibiotics R&D Market; Acurx Pharmaceuticals Ibezapolstat Program Is Helping Level The Field (NASDAQ: ACXP)
August 12, 2021
Via
AB Newswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.